(23 days)
Not Found
Not Found
No
The document describes a human plasma control product used for quality control in coagulation testing. There is no mention of AI or ML technology in the intended use, device description, or performance studies.
No
The device is a quality control product for coagulation testing, not a device used to treat a disease or condition.
No
Explanation: The device is a "human plasma control" used for quality control in coagulation testing. It is a control substance, not a medical device that diagnoses a disease or condition itself.
No
The device is a lyophilized human plasma-based product, which is a physical substance, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states it is a "human plasma control that is suitable for use as an abnormal control with patient citrated plasma in the one-stage prothrombin time (PT), in the activated partial thromboplastin time (APTT), the chromogenic Antithrombin III (AT-III) assay and in fibrinogen determinations using a clotting method." These are all in vitro diagnostic tests performed on patient samples (plasma).
- Function: It is used as a "means of quality control for coagulation testing," which is a crucial part of ensuring the accuracy and reliability of in vitro diagnostic procedures.
- Device Description: It is a "lyophilized human plasma based product," designed to be reconstituted and used in laboratory testing.
- Intended User/Care Setting: It is intended for use in a "Coagulation laboratory," which is where in vitro diagnostic tests for coagulation are performed.
The definition of an IVD is a medical device that is used to perform tests on samples taken from the human body (such as blood, urine, or tissue) to provide information for diagnosis, monitoring, or screening. The Sigma Diagnostics ACCUCLOT™ CONTROL II fits this definition perfectly as it is used in conjunction with patient plasma samples to ensure the quality of diagnostic tests.
N/A
Intended Use / Indications for Use
Sigma Diagnostics ACCUCLOT™ CONTROL II is a human plasma control that is suitable for use as an abnormal control with patient citrated plasma in the one-stage prothrombin time (PT), in the activated partial thromboplastin time (APTT), the chromogenic Antithrombin III (AT-III) assay and in fibrinogen determinations using a clotting method. Plasma controls are routinely used in the coagulation laboratory as a means of quality control for coagulation testing.
Product codes
GGC, GGN
Device Description
Sigma Diagnostics ACCUCLOT™ Control II is a human plasma control that is suitable for use as a abnormal control with patient citrated plasma in the one-stage prothrombin time (PT), in the activated partial thromboplastin time (APTT), in the chromogenic Antithrombin III (AT-III) assay and in fibrinogen determinations using a clotting method.
Sigma Diagnostics ACCUCLOT™ Control II is a lyophilized human plasma based product. After reconstitution with water, ACCUCLOT™ Control II is stable for 48 hours when stored at 2-8°C.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The safety and effectiveness of the Sigma Diagnostics ACCUCLOT™ Control II has been demonstrated by its substantial equivalence to the Sigma Diagnostics Coagulation Control, Level II (Cat. No. 8916).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Sigma Diagnostics Coagulation Control, Level II (Cat. No. 8916)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 864.5425 Multipurpose system for in vitro coagulation studies.
(a)
Identification. A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.(b)
Classification. Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
0
APR 2 9 1998 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS ACCUCLOTTM Control II, Cat. No. A5089
Sigma Diagnostics ACCUCLOT™ Control II is a human plasma control that is suitable for use as a abnormal control with patient citrated plasma in the one-stage prothrombin time (PT), in the activated partial thromboplastin time (APTT), in the chromogenic Antithrombin III (AT-III) assay and in fibrinogen determinations using a clotting method.
The safety and effectiveness of the Sigma Diagnostics ACCUCLOT™ Control II has been demonstrated by its substantial equivalence to the Sigma Diagnostics Coagulation Control, Level II (Cat. No. 8916). >>
Sigma Diagnostics ACCUCLOT™ Control II is a lyophilized human plasma based product. After reconstitution with water, ACCUCLOT™ Control II is stable for 48 hours when stored at 2-8°C.
1
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services (HHS). The logo features the HHS emblem, which is a stylized representation of a human figure. The emblem is positioned to the right of the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA", which is arranged in a circular pattern around the emblem.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
APR 2 9 1998
William Gilbert, Ph.D. . Manager, Scientific Affairs Sigma Diagnostics Inc. 545 South Ewing Avenue St. Louis, Missouri 63103
Re : K981254 ACCUCLOT™ Control II Regulatory Class: II Product Code: GGC, GGN Dated: April 2, 1998 Received: April 6, 1998
Dear Dr. Gilbert:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions aqainst misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set --forth in the Quality System Regulation (QS) for Medical Devices: General requlation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to . comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Litman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(k) Number (if known): _ 1298 / 7
Device Name: Sigma Diagnostics ACCUCLOT™ CONTROL II
Indications For Use:
Sigma Diagnostics ACCUCLOT™ CONTROL II is a human plasma control that is suitable for use as an abnormal control with patient citrated plasma in the one-stage prothrombin time (PT), in the activated partial thromboplastin time (APTT), the chromogenic Antithrombin III (AT-III) assay and in fibrinogen determinations using a clotting method. Plasma controls are routinely used in the coagulation laboratory as a means of quality control for coagulation testing.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number. K981254
Prescription Use__
(Per 21 CFR 801.109)
OR
Over-The-Counter Use__